Company type | Sociedad Anónima |
---|---|
BMAD: ZEL | |
ISIN | ES0184940817 |
Industry | Pharmaceutical |
Founded | Vigo, Galicia, Spain (August 3, 1939 ) |
Defunct | 2015 |
Headquarters | Madrid , Spain |
Area served | Worldwide |
Key people | José Fernández Sousa-Faro (Chairman) |
Products | Pharmaceuticals |
Revenue | US$176 million (2009) |
(US$46.3) million (2009) | |
(US$40.3) million (2009) | |
Total assets | US$302.9 million (2009) |
Total equity | US$59 million (2009) |
Subsidiaries | PharmaMar, Genómica, Sylentis, Zelnova, Xylazel |
Website |
www |
Footnotes / references [finan 1] [history 1] |
Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product. [history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns. [history 3]
In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal. [1]
The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.
In 2018 PharmaMar sells Xylazel to the Dutch company AkzoNobel. [2] [3]
In 2019 PharmaMar sells Zelnova, the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for 33 million euros. [4]
Direct subsidiaries as of 2009 were: [finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.
Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were: [finan 2] Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd.
A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A. [finan 2]